244 related articles for article (PubMed ID: 33303745)
1. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.
Gómez-Aleza C; Nguyen B; Yoldi G; Ciscar M; Barranco A; Hernández-Jiménez E; Maetens M; Salgado R; Zafeiroglou M; Pellegrini P; Venet D; Garaud S; Trinidad EM; Benítez S; Vuylsteke P; Polastro L; Wildiers H; Simon P; Lindeman G; Larsimont D; Van den Eynden G; Velghe C; Rothé F; Willard-Gallo K; Michiels S; Muñoz P; Walzer T; Planelles L; Penninger J; Azim HA; Loi S; Piccart M; Sotiriou C; González-Suárez E
Nat Commun; 2020 Dec; 11(1):6335. PubMed ID: 33303745
[TBL] [Abstract][Full Text] [Related]
2. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M
Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RANK signaling as a potential immunotherapy in breast cancer.
Gómez-Aleza C; González-Suárez E
Oncoimmunology; 2021 May; 10(1):1923156. PubMed ID: 34026334
[TBL] [Abstract][Full Text] [Related]
4. The Roadmap of RANKL/RANK Pathway in Cancer.
Casimiro S; Vilhais G; Gomes I; Costa L
Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
[TBL] [Abstract][Full Text] [Related]
5. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
6. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
[TBL] [Abstract][Full Text] [Related]
7. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
8. RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.
Ciscar M; Trinidad EM; Perez-Chacon G; Alsaleem M; Jimenez M; Jimenez-Santos MJ; Perez-Montoyo H; Sanz-Moreno A; Vethencourt A; Toss M; Petit A; Soler-Monso MT; Lopez V; Gomez-Miragaya J; Gomez-Aleza C; Dobrolecki LE; Lewis MT; Bruna A; Mouron S; Quintela-Fandino M; Al-Shahrour F; Martinez-Aranda A; Sierra A; Green AR; Rakha E; Gonzalez-Suarez E
EMBO Mol Med; 2023 Apr; 15(4):e16715. PubMed ID: 36880458
[TBL] [Abstract][Full Text] [Related]
9. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
[TBL] [Abstract][Full Text] [Related]
10. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.
Simatou A; Sarantis P; Koustas E; Papavassiliou AG; Karamouzis MV
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066388
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
12. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
14. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
15. ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth.
Wang Y; Luo M; Chen Y; Wang Y; Zhang B; Ren Z; Bao L; Wang Y; Wang JE; Fu YX; Luo W; Wang Y
Cancer Res; 2021 Jan; 81(1):174-186. PubMed ID: 33148660
[TBL] [Abstract][Full Text] [Related]
16. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
Pellom ST; Dudimah DF; Thounaojam MC; Uzhachenko RV; Singhal A; Richmond A; Shanker A
Oncotarget; 2017 Jan; 8(5):8604-8621. PubMed ID: 28052005
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous RANK-RANKL Signaling Upregulates CD8-Mediated Antiviral Immunity during Herpes simplex Virus Infection by Preventing Virus-Induced Langerhans Cell Apoptosis.
Klenner L; Hafezi W; Clausen BE; Lorentzen EU; Luger TA; Beissert S; Kühn JE; Loser K
J Invest Dermatol; 2015 Nov; 135(11):2676-2687. PubMed ID: 26076314
[TBL] [Abstract][Full Text] [Related]
19. SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells.
Carmona-Rodríguez L; Martínez-Rey D; Fernández-Aceñero MJ; González-Martín A; Paz-Cabezas M; Rodríguez-Rodríguez N; Pérez-Villamil B; Sáez ME; Díaz-Rubio E; Mira E; Mañes S
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591431
[TBL] [Abstract][Full Text] [Related]
20. RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling.
Sirinian C; Papanastasiou AD; Schizas M; Spella M; Stathopoulos GT; Repanti M; Zarkadis IK; King TA; Kalofonos HP
Oncogene; 2018 Sep; 37(37):5101-5114. PubMed ID: 29844572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
